Arrow Dx develops highly sensitive detection chips utilizing nanotechnology and artificial intelligence to enable early screening for non-alcoholic fatty liver disease (NAFLD) and other health conditions. This technology provides a cost-effective, portable alternative to liver biopsies, facilitating rapid diagnostics for healthcare providers and public health authorities.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Non-alcoholic fatty liver disease (NAFLD) affects a significant portion of the population and is often asymptomatic in early stages, making detection challenging. Current diagnostic methods, such as liver biopsies, are invasive, costly, and not suitable for routine screening. This lack of accessible and early detection methods hinders timely intervention and management of the disease.
Solution
Arrow Dx is developing highly sensitive detection chips utilizing nanotechnology and artificial intelligence to enable early screening for NAFLD and other diseases. These chips can be incorporated into portable sensors, offering a non-invasive and cost-effective alternative to traditional liver biopsies. The technology enhances the detection of chemical and biological molecules in solution, facilitating rapid and reliable diagnostics at the point of care. By enabling early diagnosis, Arrow Dx aims to improve patient outcomes and reduce the economic burden associated with advanced liver diseases. The platform is designed to be flexible and adaptable for a wide range of applications, including virus/bacteria detection and soil/water diagnostics.
Target Audience
The primary target audience includes healthcare providers, public health authorities, and researchers focused on early disease detection and management, as well as industries requiring environmental pollutant detection and quality control.
Features
- Nanotechnology-based detection chips for enhanced sensitivity to chemical and biological molecules.
- AI-powered analysis for accurate and rapid diagnostic results.
- Portable sensor integration for point-of-care testing.
- Non-invasive alternative to liver biopsies.
- Adaptable platform for various diagnostic applications, including NAFLD, virus/bacteria detection, and environmental monitoring.
- Machine learning software applications for data analysis and pattern recognition.